The Exodus of Imported Drugs Multinational Pharma's Struggles in China and the Golden Era for Domestic Pharma's Global Ambitions

Oct 29, 2025

Leave a message

Recently, China's National Medical Products Administration (NMPA) revoked 80 drug registration certificates in one go, with over 55% belonging to foreign or joint-venture companies, sparking widespread industry debate

. Companies like Pfizer, GlaxoSmithKline (GSK), and Janssen (a subsidiary of Johnson & Johnson) have seen multiple products exit the Chinese market. Meanwhile, originator drugs failed to secure any bids in the 10th National Centralized Drug Procurement (NCMP), marking a pivotal shift. This exodus of imported drugs is no accident-it reflects profound transformations in China's pharmaceutical landscape and ushers in an unprecedented era of opportunity for domestic players.

​I. Imported Drug Withdrawal: A Collision of Policy Pressures and Strategic Shifts​

The retreat of imported drugs stems from two key forces: the profit squeeze from NCMP and multinational pharma's global realignment.

​NCMP Squeezes Margins​

China's NCMP, which aggregates nationwide hospital procurement needs to negotiate bulk discounts, has forced originator drugmakers into a dilemma: drastically cut prices to retain market share or exit entirely. For example, Merck's posaconazole injection, priced at ¥1,400 per vial, faced competition from domestic generics costing just ¥40-a 30-fold gap that made participation untenable

.

​Multinationals Prioritize Innovation​

With patents expiring and generics eroding market share, multinationals are redirecting resources toward high-margin, high-risk areas like oncology and rare diseases. Boehringer Ingelheim's pre-emptive withdrawal of its metformin/ertugliflozin combination from the 11th NCMP exemplifies this strategic pivot

​II. Originators vs. Generics: Bridging the Quality Gap, but Trust Remains Elusive​

While regulatory frameworks have narrowed the quality divide, consumer skepticism persists.

​Chemical Equivalence, Process Variability​

Generics and originators share identical active ingredients, but differences in crystallinity, excipients, and manufacturing processes can affect efficacy. For instance, inconsistent polymorphism in generics might alter absorption rates

.

​Consistency Evaluation Validates Efficacy​

Since 2016, China's Consistency Evaluation program has mandated generics meet originator benchmarks. A 2019 real-world study by the National Healthcare Security Administration (NHSA) confirmed no statistically significant differences in safety or efficacy between 14 generics and their originators

. Rising patient trust in generics further accelerates market substitution.

​III. Domestic Pharma's Tailwinds: Policy Tailwinds and Industrial Upgrading​

The vacuum left by imported drugs creates strategic advantages for Chinese players:

​NCMP Rule Refinements​

The 11th NCMP introduced "anti-price wars" measures, including cost transparency requirements and volume guarantees for established market leaders. This stabilizes revenue for compliant companies while discouraging predatory pricing

.

​Innovation-Driven Growth​

NCMP savings fund R&D: 80% of innovative drugs now secure reimbursement within two years of approval, reducing financial risks. Leading firms like Innovent Biologics and BeiGene leverage scale to maintain 50% gross margins despite pricing pressures

.

​Industry Consolidation​

The CR10 (top 10 firms' market share) surged from 35% in 2023 to 50% in 2025, concentrating resources in innovation-focused players

​IV. Global Ambitions: From "Made in China" to "Invented in China"​​

Domestic pharma's internationalization is accelerating, driven by regulatory alignment and strategic partnerships:

​Quality Benchmarking​

Dozens of Chinese manufacturers now meet FDA and EMA standards. For example, Innovent's sintilimab and Hengrui's PD-1 inhibitors received U.S. approvals, signaling global recognition

.

​Record-Breaking Licensing Deals​

In 2025 alone, Chinese biotechs inked 93 overseas licensing agreements worth 85billion,withHengrui's12 billion pact with GSK setting a new milestone

. This reflects international pharma's appetite for China's cost-efficient innovation.

​Diversified Globalization Strategies​

​Regional Expansion: Prioritizing Brazil, the Middle East/North Africa, and Eastern Europe for generics, while targeting Japan and Southeast Asia for complex therapies.

​Model Evolution: Transitioning from "pure licensing" to co-development (e.g., BeiGene's collaboration with Novartis) and NewCo ventures (e.g., Hengrui's joint ventures with global funds)

Conclusion: From Survival to Supremacy​

The withdrawal of imported generics is not a decline but a recalibration. As China tightens quality controls and rewards innovation, domestic players are transitioning from cost arbitrage to value creation. With 30% of global R&D pipelines now originating in China, the world's pharmaceutical hierarchy is being reshaped-one breakthrough at a time.

Send Inquiry